水飞蓟提取物 
英文名称：Milk Thistle Extract 
CAS: 84604-20-6 
分子式: C25H22O10 
分子量: 482.4388 
植物来源: 菊科水飞蓟属植物水飞蓟Silybum marianum （L.） Gaertn.[Carduus marianus L.]，的全草及瘦果。以瘦果入药。 
有效成分:水飞蓟中的主要有效成分是黄酮类物质,包括:水飞蓟宾(Silybinin) A、B、水飞蓟宁(Silydianin)、水飞蓟亭(Silychristin)、Dehydrosilybinin、Isosilybinin A、B等,总称为水飞蓟素(silymarin) 
检测方法：HPLC UV 
产品规格：水飞蓟素 ≥80.0%（HPLC） 
产品性状：淡黄色粉末 
产品用途： 
1. 保肝作用 
水飞蓟素为保肝的主要活性成分, 具有再生作用, 可刺激新的肝细胞形成, 改善肝功能; 同时具有肝细胞膜保护作用, 预防细胞毒素浸润肝细胞, 并提高膜结构缺损的恢复能力。 
用于肝炎，尚可用于治疗肝硬化，脂肪肝，酒精引起的肝损害，代谢中毒性肝损伤、胆结石和脾脏病等 
2. 抗氧化 
水飞蓟素的酚羟基提供氢原子而有强大的抗氧化作用。它们具有清除自由基特性,抗脂质过氧化活性。 
3. 降血脂 
水飞蓟宾能抑制成年大鼠心肌细胞质膜Ca2+通道, 抑制食物诱导的血胆固醇过高,降低极低密度脂蛋白 (VLDL) 与低密度脂蛋白 (LDL), 升高高密度脂蛋白 (HDL), 可用于心血管系统疾病的治疗。 
【临床功效】 
水飞蓟提取物主要用于病毒性肝炎、急慢性肝炎、肝硬化、高脂肪肝、营养代谢性疾病和心血管疾病。 
包装规格：25公斤/纸板桶或根据客户需要定制包装 
保质期：24个月

产品详询:13657416805

参考文献：

1. 1. 

   Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States. The Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol. 2013;178:38–45.

2. 2. 

   Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.

3. 3. 

   Abenavoli L, Aviello G, Capasso R, Milic N, Capasso F. Milk thistle for treatment of nonalcoholic fatty liver disease. Hepat Mon. 2011;11:173–7.

4. 4. 

   Pasumarthy L, Srour J. Nonalcoholic steatohepatitis: a review of the literature and updates in management. South Med J. 2010;103:547–50.

5. 5. 

   Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. AM J Gastroenterol. 2003;98:960–7.

6. 6. 

   Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–73.

7. 7. 

   Burczynski FJ, Wang G, Nguyen D, Chen Y, Smith HJ, Gong Y. Silymarin and hepatoprotection. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012;37:6–10.

8. 8. 

   Li CC, Hsiang CY, Wu SL, Ho TY. Identification of novel mechanisms of silymarin on the carbon tetrachloride-induced liver fibrosis in mice by nuclear factor-κB bioluminescent imaging-guided transcriptomic analysis. Food Chem Toxicol. 2012;50:1568–75.

9. 9. 

   George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol. 2003;39:756–64.

10. 10. 

    Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519–23.

11. 11. 

    Kwon DY, Ahn CW, Choi YJ, Kim YC. Induction of hepatic glutathione synthesis via alterations in sulfur amino acid metabolism in mice treated with silymarin acutely. FASEB J. 2013;27(805):1.

12. 12. 

    Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology. 1996;23:749–54.

13. 13. 

    Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol. 2003;37:336–9.

14. 14. 

    Kim M, Yang S-G, Kim JM, Lee J-W, Kim YS, Lee JI. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells. Int J Mol Med. 2012;30:473–9.

15. 15. 

    Reddy KR, Belle SH, Fried MW, Afdhal N, Navarro VJ, Hawke RL. Rationale, challenges, and participants in a phase II trial of a botanical product for chronic hepatitis C. Clin Trials. 2012;9:102–12.

16. 16. 

    Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol. 1982;17:517–21.

17. 17. 

    Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989;9:105–13.

18. 18. 

    Feher J, Deak G, Muzes G, et al. Hepatoprotective activity of silymarin (Legalon) therapy in patients with chronic liver disease. Orv Hetil. 1989;130:2723–7.

19. 19. 

    Müzes G, Deák G, Láng I, Nékám K, Niederland V, Fehér J. Effect of silimarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind protocol). Orv Hetil. 1990;22;131:863–6. Hungarian.

20. 20. 

    Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol. 1997;26:871–9.

21. 21. 

    Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61:2035–63.

22. 22. 

    Lucena MI, Andrade RJ, de la Cruz JP, Rodriguez-Mendizabal M, Blanco E, Sánchez-de la Cuesta F. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. Int J Clin Pharmacol Ther. 2002;40:2–8.

23. 23. 

    Lirussi F, Okolicsanyi L. Cytoprotection in the nineties: experience with ursodeoxycholic acid and silymarin in chronic liver disease. Acta Physiol Hung. 1992;80:363–7.

24. 24. 

    Buturova LI, Tsybizova TA, Kalinin AV. Use of Legalon in non-alcoholic fatty liver disease [in Russian]. Eksp Klin Gastroenterol. 2010;5:69–75.

25. 25. 

    Fujii M, Shibazaki Y, Wakamatsu K, et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 2013;46:141–52.

26. 26. 

    Kleiner DE, Brunt EM, Van Natta M, Nonalcoholic Steatohepatitis Clinical Research Network, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.

27. 27. 

    Klein T, Fujii M, Sandel J, et al. Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis. Med Mol Morphol. 2013 [Epub ahead of print] PubMed PMID: 24048504.

28. 28. 

    Traber PG, Zomer E. Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 2013;8:e83481.

29. 29. 

    Kawai D, Takaki A, Nakatsuka A, et al. Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. Hepatology. 2012;56:912–21.

30. 30. 

    Cynis H, Kehlen A, Haegele M, et al. Inhibition of glutaminyl cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice. Int J Exp Pathol. 2013;94:217–25.

31. 31. 

    Nobili V, Svegliati-Baroni G, Alisi A, Miele L, Valenti L, Vajro P. A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol. 2013;58:1218–29.

32. 32. 

    Huseini HF, Larijani B, Heshmat R, et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res. 2006;20:1036–9.

33. 33. 

    Hussain SA. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. J Med Food. 2007;10:543–7.

34. 34. 

    Yao J, Zhi M, Gao X, Hu P, Li C, Yang X. Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz J Med Biol Res. 2013;46:270–7.

35. 35. 

    Trappoliere M, Caligiuri A, Schmid M, et al. Silybin, a component of silymarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol. 2009;50:1102–11.

36. 36. 

    Sajedianfard J, Behroozi Z, Nazifi S. The effects of a hydroalcoholic extract of silymarin on serum lipids profiles in streptozotocin induced diabetic rats. Comp Clin Pathol. 2014;23:779–84.

37. 37. 

    Metwally MAA, El-Gellal AM, El-Sawaisi SM. Effects of silymarin on lipid metabolism in rats. World Appl Sci J. 2009;6:1634–7.